Health Care & Life Sciences » Biotechnology | Anavex Life Sciences Corp.

Anavex Life Sciences Corp.

Anavex Life Sciences Corp.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
45.43 M
Public Float
42.13 M
Anavex Life Sciences Corp.
Stock Exchange NASDAQ Stock Market
EPS
$0.51
Market Cap
$174.92 M
Shares Outstanding
50.41 M
Public Float
44.54 M

Profile

Address
51 West 52nd Street
New York New York 10019
United States
Employees -
Website http://www.anavex.com
Updated 07/08/2019
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Financials

View All

Christopher U. Missling
President, CEO, Secretary & Director
Claus van der Velden
Director